Article Text

Download PDFPDF
Correspondence on “Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry” by Machado et al
  1. Rim Bourguiba1,2,3,
  2. Marion Delplanque1,2,3,
  3. Léa Savey1,2,3,
  4. Veronique Hentgen4,
  5. Gilles Grateau1,2,3,
  6. Sophie Georgin-lavialle1,2,3,5
  7. French national reference Center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)
  1. 1 Internal Medecine, Hopital Tenon, Paris, Île-de-France, France
  2. 2 Service de médecine interne, Hopital Tenon, Paris, France
  3. 3 UMR_S 933, Sorbonne Universités, UPMC Univ Paris 06, Paris, Île-de-France, France
  4. 4 CeReMAI-Departement of pediatrics, Hôpital Mignot, Le Chesnay, France
  5. 5 Tenon Hospital, Internal Medicine, AP-HP, Paris, France
  1. Correspondence to Dr Rim Bourguiba, Internal Medecine, Hopital Tenon, Paris, France; rim.bourguiba{at}outlook.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Machado et al who describe safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal disease.1 The authors observed that vaccine against SARS-CoV-2 is well tolerated with rare report of I-RMD flare and very rare reports of serious adverse events.

We observed that the authors included only 27 patients with autoinflammatory diseases. We thus propose to complete their observation with the result of our study about 190 patients with autoinflammatory disease (AID).

A web survey assessing adverse effects after COVID-19 vaccination was sent on 7–30 June 2021 to patients with AID followed in the French national adult AID reference centre, and already included in the Juvenile Inflammatory Rheumatism (JIR) cohort. The patients were asked whether they had received a COVID-19 vaccination, the type of vaccine and number of injections. Severe adverse events were defined by the need for hospitalisation. Local reaction, fever, headache, arthralgia, myalgia, allergic reaction, fatigue, nausea, …

View Full Text

Footnotes

  • Handling editor Josef S Smolen

  • Twitter @Rimbourguiba1, @SophieGeorgin

  • Contributors All authors contributed in writing and conception of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.